Nuvalent (NUVL) Q2 R&D Up 65%

Nuvalent (NASDAQ:NUVL), a clinical-stage biotechnology company developing therapies for cancers driven by kinase mutations, released its second quarter 2025 earnings results on August 7, 2025. There was no product revenue, consistent with expectations for a pre-commercial biotech. Overall, the company advanced its oncology pipeline and continued its push toward regulatory milestones, at the cost of higher spending and a widening GAAP net loss. Source: Analyst estimates for the quarter provided by FactSet. Nuvalent is a biotechnology company that discovers and develops small molecule therapies for cancers with specific genetic drivers. It concentrates on designing drugs that target genetic mutations known as kinases, which can fuel the growth of certain tumors. Its most advanced programs focus on lung cancer, where kinase mutations play a leading role.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool